Resources
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Therapy Designation to Alixorexton for the Treatment of Narcolepsy Type 1
2
FDA Accepts Investigational New Drug Application for COMP360 for PTSD
3
Neurosterix Announces Phase 1 Study of NTX-253 for Schizophrenia
4
New Phase 3 Clinical Vocal Biomarker Data on Brilaroxazine to Treat Negative Symptoms in Schizophrenia
5